This text is a result of machine translation.
China's First Oral COVID-19 Antiviral Medicine in Dispute
An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.
Aug 08, 2022 09:00 AM
913 companies have been investigated by public funds since the second quarter, and the six top flow fund managers focus on the leaders of subdivided industries
China's First Modified New Drug of Docetaxel Successfully Went to the US
Feb 19, 2025 10:41 AM
A number of enterprises on the science and innovation board are listed on the "white list" of key enterprises for operation guarantee and transfer
Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab
The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.
Sep 20, 2022 03:35 PM
Fengtai District of Beijing will lift the epidemic prevention zone of the whole region from now on.
Hong Kong stocks continued to rise in the anti epidemic sector, and Junshi biology rose nearly 17%
China's New Energy Intelligent Vehicle Industry Chain Enterprises Have Opened a New Era
Feb 27, 2025 03:42 PM
AIEV Leads the Way into a New Era of Automotive Intelligence
Feb 27, 2025 03:27 PM
Witnessing History: The New Globalization Landscape of 2025 (Part II)
Feb 24, 2025 09:49 PM